We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2002 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
ClinicalTrials.gov Identifier:
First Posted: February 27, 2004
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Cancer Institute (NCI)

RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.

PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.

Condition Intervention Phase
Precancerous Condition Biological: autologous tumor cell vaccine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: December 1971
Detailed Description:

OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.

OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   1 Year and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx requiring surgery at least 4 times per year Condition must have existed for more than 1 year

PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified

PRIOR CONCURRENT THERAPY: See Disease Characteristics

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002454

United States, New Jersey
New Jersey Medical School
Newark, New Jersey, United States, 07103-2714
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
Study Chair: James M. Oleske, MD Rutgers, The State University of New Jersey
  More Information

Oleske J, Fishman D, Cooper R, et al.: Autogenous vaccine in the treatment of laryngeal papilloma. In: Proceeding of the 12th International Congress of Chemotherapy, 1981. pp 1099-1101.

ClinicalTrials.gov Identifier: NCT00002454     History of Changes
Other Study ID Numbers: CDR0000071657
First Submitted: November 1, 1999
First Posted: February 27, 2004
Last Update Posted: October 12, 2017
Last Verified: January 2002

Keywords provided by National Cancer Institute (NCI):
lung papilloma

Additional relevant MeSH terms:
Precancerous Conditions
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs